The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$11.48M | 4 yrs ago

About PolyActiva

PolyActiva uses a drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films or fibres. PolyActiva's platform technology is used to make plastic components for medical devices from drugs. The manufacture process provides greater flexibility over the composition of the final material, and better product outcomes compared with competitor technologies. The manufacture process is also scalable and can easily be adapted to existing device component production processes. PolyActiva has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology.

PolyActiva Headquarter Location

Level 9 31 Queen St

Melbourne, Victoria, 3000,


+61 3 9657 0700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PolyActiva

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PolyActiva is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,315 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health IT

7,900 items

PolyActiva Patents

PolyActiva has filed 9 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Dosage forms
  • Polymers
patents chart

Application Date

Grant Date


Related Topics




Polymers, Polymer chemistry, Drug delivery devices, Dosage forms, Polymerization reactions


Application Date


Grant Date



Related Topics

Polymers, Polymer chemistry, Drug delivery devices, Dosage forms, Polymerization reactions



Latest PolyActiva News

Susvimo noninferior to monthly ranibizumab with similar efficacy

Mar 31, 2022

Disclosures: Holekamp reports being on the advisory board for Acucela, Adverum, Allergan, Annexon, Apellis, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Kodiak Sciences, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, Regeneron and Stealth; receiving financial support from Gemini, Genentech and Gyroscope; lecturing for Allergan, Bayer, Novartis, Regeneron and Spark; receiving nonfinancial support from Genentech; having patents with Katalyst Surgical; and being an equity owner in Katalyst Surgical. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio The Port Delivery System with ranibizumab was noninferior and had similar efficacy to monthly ranibizumab injections for the treatment of neovascular age-related macular degeneration, according to results from the Archway trial. The novel treatment delivery method, which was approved by the FDA in October 2021 and is now known as Susvimo (Genentech), allows ranibizumab to be continuously delivered into the vitreous via a refillable ocular implant, reducing the treatment and monitoring burden. The phase 3 open-label, randomized, visual acuity assessor-masked noninferiority and equivalence Archway trial included patients with neovascular AMD who were previously treated with and responsive to anti-VEGF therapy. The study included 418 patients who were randomly assigned to treatment with the Port Delivery System (PDS) with ranibizumab 100 mg/mL with fixed 24-week refill exchanges or intravitreal ranibizumab 0.5 mg injections monthly. The adjusted mean change in best corrected visual acuity from baseline, over weeks 36 and 40, was +0.2 letters in the PDS arm and +0.5 letters in the monthly injection arm. Ocular adverse events were reported in 47 patients (19%) in the PDS arm and 10 patients (6%) in the monthly injection arm. Most adverse events in the PDS arm occurred within 1 month of implantation. “Supported by a strong patient preference over intravitreal injections, the PDS has the potential to help reduce frequent visits for treatment and to improve outcomes in patients with [neovascular] AMD in clinical practice,” Nancy M. Holekamp, MD, and colleagues wrote. Read more about

PolyActiva Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PolyActiva Rank

  • When was PolyActiva founded?

    PolyActiva was founded in 2010.

  • Where is PolyActiva's headquarters?

    PolyActiva's headquarters is located at Level 9, Melbourne.

  • What is PolyActiva's latest funding round?

    PolyActiva's latest funding round is Series C.

  • How much did PolyActiva raise?

    PolyActiva raised a total of $22.73M.

  • Who are the investors of PolyActiva?

    Investors of PolyActiva include Brandon Capital Partners, Yuuwa Capital and Medical Research Commercialisation Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.